2LOK

Solution NMR Structure of the uncharacterized protein from gene locus VNG_0733H of Halobacterium salinarium, Northeast Structural Genomics Consortium Target HsR50

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
2	2D 1H-13C HSQC	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
3	3D HNCO	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
4	3D CBCA(CO)NH	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
5	3D HNCACB	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
6	3D 1H-13C arom NOESY	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
7	cCH_NOESY	0.800 mM [U-100% 13C; U-100% 15N;U-2H] hsr50.009, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
8	nNH_NOESY	0.800 mM [U-100% 13C; U-100% 15N;U-2H] hsr50.009, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
9	3D HNHA	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
10	3D 1H-13C NOESY	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
11	3D HCCH-TOCSY	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
12	3D 1H-13C NOESY aliphatic	0.800 mM [U-100% 13C; U-100% 15N;U-2H] hsr50.009, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
13	3D 1H-13C NOESY aliphatic	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
14	3D 1H-13C NOESY aromatic	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
15	3D 1H-15N NOESY	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
16	3D 1H-15N NOESY	0.800 mM [U-100% 13C; U-100% 15N;U-2H] hsr50.009, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
17	2D 1H-15N HSQC	0.674 mM [U-100% 13C; U-100% 15N] hsr50.007, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298
18	3D HA(CO)NH	0.726 mM [U-100% 13C; U-100% 15N] hsr50.005, 1 x Proteinase Inhibitors, 0.02 % NaN3, 10 mM DTT, 5 mM CaCL2, 200 mM NaCL, 20 mM MES pH 6.5, 10 % D2O, 50 uM DSS	95% H2O/5% D2O		6.5	ambient	298

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	Avance	800
2	Bruker	Avance	900
3	Varian	INOVA	600

NMR Refinement
Method	Details	Software
molecular dynamics	cns 1.3 with RDC, noe, dihedral and h-bonds constraints using PARAM19 force field.	CNS

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	100
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	refinement	CNS		Brunger, Adams, Clore, Gros, Nilges and Read
2	structure solution	CNS		Brunger, Adams, Clore, Gros, Nilges and Read
3	geometry optimization	CNS		Brunger, Adams, Clore, Gros, Nilges and Read
4	refinement	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
5	geometry optimization	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
6	structure solution	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
7	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
8	collection	TOPSPIN		Bruker Biospin
9	chemical shift assignment	PINE		Bahrami, Markley, Assadi, and Eghbalnia
10	data analysis	SPARKY		Goddard
11	geometry optimization	TALOS+		Shen, Cornilescu, Delaglio and Bax
12	geometry optimization	PALES		PALES (Zweckstetter, Bax)
13	structure validation	PSVS		Bhattacharya, Montelione
14	structure validation	PDBSTAT	5.5-exp	Tejero; Montelione

RCSB PDB Core Operations are funded by the National Science Foundation (DBI-1832184), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.